These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10942387)

  • 21. [Staphylokinase and its mutants: a new generation of thrombolytic agents].
    Lebrazi J; Elalamy I; Helft G; Samama MM
    J Mal Vasc; 1998 Apr; 23(2):92-8. PubMed ID: 9608920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High resolution mapping of the B cell epitopes of staphylokinase in humans using negative selection of a phage-displayed antigen library.
    Jenné S; Brepoels K; Collen D; Jespers L
    J Immunol; 1998 Sep; 161(6):3161-8. PubMed ID: 9743384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Staphylokinase for a better thrombolytic treatment of heart and platelet diseases].
    Vanderschueren S
    Verh K Acad Geneeskd Belg; 2000; 62(1):69-75. PubMed ID: 10769618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Staphylokinase-specific cell-mediated immunity in humans.
    Warmerdam PA; Vanderlick K; Vandervoort P; De Smedt H; Plaisance S; De Maeyer M; Collen D
    J Immunol; 2002 Jan; 168(1):155-61. PubMed ID: 11751958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High yield production and purification of recombinant staphylokinase for thrombolytic therapy.
    Schlott B; Hartmann M; Gührs KH; Birch-Hirschfeid E; Pohl HD; Vanderschueren S; Van de Werf F; Michoel A; Collen D; Behnke D
    Biotechnology (N Y); 1994 Feb; 12(2):185-9. PubMed ID: 7764434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the immunogenicity of recombinant staphylokinase in patients and in animal models.
    Vanderschueren SM; Stassen JM; Collen D
    Thromb Haemost; 1994 Aug; 72(2):297-301. PubMed ID: 7831668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
    Collen D; Lijnen HR; Vanderschueren S
    Verh K Acad Geneeskd Belg; 1995; 57(3):183-96; discussion 196-8. PubMed ID: 7483814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of a staphylokinase: variant a model for reduced antigenicity.
    Chen Y; Song G; Jiang F; Feng L; Zhang X; Ding Y; Bartlam M; Yang A; Ma X; Ye S; Liu Y; Tang H; Song H; Rao Z
    Eur J Biochem; 2002 Jan; 269(2):705-11. PubMed ID: 11856331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycosylation of asparagine-28 of recombinant staphylokinase with high-mannose-type oligosaccharides results in a protein with highly attenuated plasminogen activator activity.
    Miele RG; Prorok M; Costa VA; Castellino FJ
    J Biol Chem; 1999 Mar; 274(12):7769-76. PubMed ID: 10075668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interactions of staphylokinase with human platelets.
    Lijnen HR; Van Hoef B; Collen D
    Thromb Haemost; 1995 Mar; 73(3):472-7. PubMed ID: 7667831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?
    Collen D; Lijnen HR
    Blood; 1994 Aug; 84(3):680-6. PubMed ID: 7519069
    [No Abstract]   [Full Text] [Related]  

  • 32. Mechanism of action and thrombolytic potential of staphylokinase.
    Lijnen HR
    Verh K Acad Geneeskd Belg; 1995; 57(4):303-14. PubMed ID: 8571666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The fibrinolytic activity of staphylokinase mutants in the fibrin plate assay.
    Hauptmann J; Gührs KH; Hartmann M; Schlott B
    Haemostasis; 1995; 25(6):272-6. PubMed ID: 8586317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and induction of circulating antibodies against recombinant staphylokinase.
    Declerck PJ; Vanderschueren S; Billiet J; Moreau H; Collen D
    Thromb Haemost; 1994 Jan; 71(1):129-33. PubMed ID: 8165631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies.
    Hu X; Zhang M; Zhang C; Long S; Wang W; Yin W; Cao Z
    J BUON; 2016; 21(6):1374-1378. PubMed ID: 28039694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epitope mapping by negative selection of randomized antigen libraries displayed on filamentous phage.
    Jespers L; Jenné S; Lasters I; Collen D
    J Mol Biol; 1997 Jun; 269(5):704-18. PubMed ID: 9223635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
    Vanderschueren S; Barrios L; Kerdsinchai P; Van den Heuvel P; Hermans L; Vrolix M; De Man F; Benit E; Muyldermans L; Collen D
    Circulation; 1995 Oct; 92(8):2044-9. PubMed ID: 7554180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.
    Szemraj J; Stankiewicz A; Rozmyslowicz-Szermińska W; Mogielnicki A; Gromotowicz A; Buczko W; Oszajca K; Bartkowiak J; Chabielska E
    Thromb Haemost; 2007 Jun; 97(6):1037-45. PubMed ID: 17549308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel recombinant thrombolytic and antithrombotic staphylokinase variants with an RGD motif at their N-termini.
    He J; Di J; Xu R; Zhao B
    Biotechnol Appl Biochem; 2008 May; 50(Pt 1):17-23. PubMed ID: 18039183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
    Aisina RB; Moukhametova LI; Varfolomeyev SD
    Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.